Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (23)

I-076Estelle Chasseloup

Regulatory-Informed Model Refinement: From Adult-Only to Adult–Pediatric PopPK Integration and its implications

Wed, Jun 3, 2026 10:30AM–12:00PM

I-077Farina Hellmann

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

Wed, Jun 3, 2026 10:30AM–12:00PM

I-078Jakob Kolar

EVALUATION OF MODEL SELECTION AND AVERAGING ALGORITHMS FOR MODEL-INFORMED PRECISION DOSING OF GENTAMICIN IN NEONATES

Wed, Jun 3, 2026 10:30AM–12:00PM

I-079Ana Rodríguez-Báez

NORMALIZATION TO BODY WEIGHT IN PAEDIATRIC PHARMACOKINETICS: IMPACT ON CLEARANCE SCALING

Wed, Jun 3, 2026 10:30AM–12:00PM

I-080Jennie van Dyk

Simulation-based guideline implementation of weight-banded dosing strategies for childhood leprosy

Wed, Jun 3, 2026 10:30AM–12:00PM

II-075Sally Babiker

Model-informed extrapolation of pyrazinamide brain exposure in children with tuberculous meningitis

Wed, Jun 3, 2026 3:20PM–4:50PM

II-076Salomé Dumasdelage

Systemic bioavailability and cortisol suppression of ocular dexamethasone in preterm infants: a PK/PD analysis

Wed, Jun 3, 2026 3:20PM–4:50PM

II-077Laura Ibarra Gomez

Model-informed approach to Support Dose Selection for Lurbinectedin in Pediatric Patients with Advanced Solid Tumors and Recurrent/Refractory Ewing Sarcoma

Wed, Jun 3, 2026 3:20PM–4:50PM

II-078Orestis Papatryfonos

MODEL-BASED META-ANALYSIS OF PARACETAMOL DOSE–RESPONSE IN PAEDIATRIC TONSILLECTOMY PAIN

Wed, Jun 3, 2026 3:20PM–4:50PM

II-079Aymara Sancho-Araiz

Quantifying the CYP3A ontogeny in the gut wall and liver using a reduced population physiologically-based pharmacokinetic model

Wed, Jun 3, 2026 3:20PM–4:50PM

II-080Jen-Hao (Eric) Wu

Population pharmacokinetic analysis of etoposide and model-based dosing evaluation in pediatric oncology

Wed, Jun 3, 2026 3:20PM–4:50PM

III-075Francesco Bellanti

Pharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy

Thu, Jun 4, 2026 9:50AM–11:20AM

III-076Nele Goeyvaerts

Population Pharmacokinetic and Pharmacodynamic Modeling of Canagliflozin in Paediatric Patients with Type 2 Diabetes Mellitus

Thu, Jun 4, 2026 9:50AM–11:20AM

III-077Sonoko Kawakatsu

Population pharmacokinetic (popPK) analysis of tenofovir alafenamide (TAF) and tenofovir (TFV) in children with HIV-1 ≥1 month of age

Thu, Jun 4, 2026 9:50AM–11:20AM

III-078Najia Rahim

Physiologically Based Pharmacokinetic Modeling of Cefotaxime to Inform Pediatric Dosing in Renal Impairment

Thu, Jun 4, 2026 9:50AM–11:20AM

III-079Mohammed Rohi Sanoufi

Population pharmacokinetics of intravenous Ceftazidime in critically ill paediatric patients

Thu, Jun 4, 2026 9:50AM–11:20AM

III-080Maria Xiberras

Pharmacodynamics of morphine and paracetamol for analgesia after paediatric cardiac surgery: A repeated time-to-event analysis

Thu, Jun 4, 2026 9:50AM–11:20AM

IV-075Laura Boles

Population pharmacokinetics and exposure-response analysis of tideglusib in children and adolescents with congenital myotonic dystrophy type 1